Earnings History Data for AEterna Zentaris Inc. (AEZS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

AEterna Zentaris Inc.

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Release Date Time Est. Time Symbol Name Market Cap (M) Rep. EPS Est. EPS Last years EPS SeekingAlpha Headline Price Change Ext. Hours Price Ext. Hours Change 52 Week Range Volume Avg. Volume Ext. Hours Volume Top Mover
28-03-2022 ?? AEZS AEterna Zentaris Inc. 43.56 -0.02 -0.02 -0.02 Aeterna Zentaris GAAP EPS of -$0.02 in-line, revenue of $1M beats by $0.37M
[3/29/2022 8:47 AM]
0.3655 0.01 
0.35 0.0 
0.29 - 1.17 452,320 540,000 2,592
05-05-2021 PM Before the open
(May 5)
AEZS AEterna Zentaris Inc. 128.42 -0.02 0.00 0.04 Aeterna Zentaris reports Q1 results
[5/5/2021 8:29 AM]
0.9579 -0.08 
0.94 -0.02 
0.29 - 3.62 3,678,850 4,050,000 1,687
05-11-2020 PM AEZS AEterna Zentaris Inc. 20.06 -0.02 0.00 -0.02 Aeterna Zentaris reports Q3 results
[11/6/2020 8:43 AM]
0.32 0.0 
0.32 0.0 
0.29 - 1.54 287,552 923,336 603